- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01437696
How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months?
How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months? - An Investigation in Veterans Living at Ste-Anne's Hospital
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objectives of the proposed 2 phase-protocol in aged Canadian veterans (n=60) are to evaluate the impact of 2000 IU/day of vitamin D3 supplementation (tablets or liquid form) on correcting low vitamin D status and the associated impact on biochemistry, bone health markers and markers of inflammation in a Fall period (Before and After, 8 weeks) and, 2) evaluate which food-based supplementation will maintain vitamin D3 status thereafter from winter through spring by measuring serum 25(OH)D concentration following intake of vitamin D delivered (with liquid form vitamin D3) using foods as the vehicle providing an additional 1000 IU/day or 500 IU/day compared to regular meals offered at Ste-Anne's Hospital (SAH) (Randomized Controlled Trial, 3 groups, 24 weeks). Anthropometry (weight, height, BMI, mid-arm and mid-calf circumferences), grip strength, biochemical markers of bone health (25(OH)D, PTH, calcium, ionized calcium and phosphate), assessments of cognitive and functional status (Mini-Mental State Evaluation, Frail Elderly Functional Assessment, Physiotherapy Functional Mobility Profile and Pain Assessment Checklist) as well as volumetric bone mineral density using peripheral quantitative computed tomography (pQCT) will be gathered.
The long-term goal of the research program is to use novel food-delivery systems and approaches to enhancing vitamin D intake that meets the needs of this population. For years, medications have been delivered through foods but few studies have applied this to natural health products such as vitamin D. In chronic care, the number of prescription pills is high often 13 or more not accounting for multiple administrations over a day. Further documentation of health related indicators such as capacity to perform daily activities and chronic pain intensity would relate to quality of life and improve our understanding of vitamin D in more than bone health related issues. The reality of long-term care facilities (financial, human and material resources) needs to be addressed for the newly developed delivery modes to meet the needs of these residents and the projected increase in care required for our aging Canadian population. Large scale interventions will need to take place to give more insight on efficacy and efficiency of this new food delivery approach.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Quebec
-
Ste. Anne-de-Bellevue, Quebec, Canada, H9X1Y9
- Ste. Anne's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All Veterans over the age of 70 years will be invited to participate given selection and exclusion criteria. Level 1, 2 and 3 care will comprise the recruitment pool. These levels of care permit such investigation and do not include those in palliative conditions.
- Individuals with chronic diseases will be permitted to participate as long as the disease is not end-stage (ie prognosis of more than 4 months).
- Not excluding co-morbidities or poor cognition is consistent with the work of others in the area.
- Lastly combined oral and enteral feeding modes will be included since the majority quickly transition to foods but some do take a meal-replacement/liquid supplement.
Exclusion Criteria:
- End-stage renal disease due to altered vitamin D metabolism and use of vitamin D analogues
- End-stage liver disease
- Untreated hyperparathyroid conditions such as cancer and metabolic bone disease except for osteoporosis and osteomalacia
- Any condition that requires enteral feeding alone as feeding route will be excluded since this oral intake, even if only partial, is a critical measurement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Vitamin D fortified food 500 IU
One portion of a specific food item will be provided each day.
500 IU Vitamin D added.
|
A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
|
|
Experimental: Vitamin D fortified food 1000 IU
One portion of a specific food item will be provided each day.
1000 IU Vitamin D added.
|
A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
|
|
Placebo Comparator: Placebo
One portion of a specific food item will be provided each day.
No vitamin D added.
|
No liquid cholecalciferol will be added to the food.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in 25(OH)D plasma concentrations
Time Frame: Baseline and following 8 weeks of the observation phase. Also following 1, 2, 3, 4, 5 and 6 months of the active supplementation phase.
|
Fasted morning blood samples will be taken monthly for assessment of 25(OH)D plasma concentrations.
|
Baseline and following 8 weeks of the observation phase. Also following 1, 2, 3, 4, 5 and 6 months of the active supplementation phase.
|
|
Changes in Vitamin D intake from foods and supplements
Time Frame: Baseline and following 8 weeks of the observation phase. Also following 2, 4 and 6 months of the active supplementation phase.
|
Using food records, vitamin intake will be assessed for 3 days.
The records will be collected by a registered dietitian.
|
Baseline and following 8 weeks of the observation phase. Also following 2, 4 and 6 months of the active supplementation phase.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in bone mineral density
Time Frame: Baseline and following 6 months of the active supplementation phase (32 week timepoint).
|
Using peripheral quantitative computed tomography (pQCT) bone mineral density will be assessed for the radius and tibia.
|
Baseline and following 6 months of the active supplementation phase (32 week timepoint).
|
|
Changes in functional mobility
Time Frame: Baseline and following 32 weeks of study involvement
|
Functional mobility will be assessed using grip strength, frail elderly functional assessment (FEFA) and physiotherapy functional mobility profile (PFMP).
The assessments will be conducted by the doctoral student and a physiotherapist.
|
Baseline and following 32 weeks of study involvement
|
|
Change in chronic pain over time
Time Frame: Baseline and following 8 weeks of the observation phase. Also following 6 months of the active supplementation phase (32 week timepoint).
|
Chronic pain will be assessed using PACSLAC: Pain Assessment Checklist for Seniors with Limited Ability to Communicate.
|
Baseline and following 8 weeks of the observation phase. Also following 6 months of the active supplementation phase (32 week timepoint).
|
|
Changes in biochemistry measurements during the study period
Time Frame: Baseline and following 8 weeks of the observation phase. Also following 2, 4 and 6 months of the active supplementation phase.
|
Fasted morning blood sample will be taken to assess calcium, ionized calcium, phosphate, glucose, sodium, potassium, albumin, hemoglobin, and total protein.
|
Baseline and following 8 weeks of the observation phase. Also following 2, 4 and 6 months of the active supplementation phase.
|
|
Changes in inflammatory markers and bone metabolism markers
Time Frame: Baseline and following 8 weeks of the observation phase. Also following 2, 4 and 6 months of the active supplementation phase.
|
Fasted morning blood sample will be taken to assess inflammatory markers: CRP, IL-6, IL-12, IL-14, and TNF alpha.
Bone metabolism will be assessed by CTX and osteocalcin.
|
Baseline and following 8 weeks of the observation phase. Also following 2, 4 and 6 months of the active supplementation phase.
|
|
Change in PTH
Time Frame: Baseline and following 8 weeks of the observation phase. Also following 1, 2, 3, 4, 5 and 6 months of the active supplementation phase.
|
Fasted morning blood samples will be taken monthly for assessment of PTH plasma concentrations.
|
Baseline and following 8 weeks of the observation phase. Also following 1, 2, 3, 4, 5 and 6 months of the active supplementation phase.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hope A Weiler, PhD, RD, McGill University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HW-11-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
University Hospital, Clermont-FerrandTerminated
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
-
Ondokuz Mayıs UniversityCompletedD Vitamin Deficiency | Osteocalcin | Gingival Crevicular FluidTurkey
-
Okan UniversityArçelik A.Ş.Completed
Clinical Trials on Vitamin D
-
University of Ilorin Teaching HospitalMayo ClinicNot yet recruitingProstate Cancer (Adenocarcinoma) | Vitamin D on Tumor Response and Inflammatory MarkersNigeria
-
PfizerTerminated
-
Wroclaw University of Health and Sport SciencesCompletedAthletes | Football Players | Exercise Physiology | Vitamin D Deficiency (10 ng/mL to 30 ng/mL)Poland
-
Universidad Autónoma Benito Juárez de OaxacaNational Council of Science and Technology, MexicoCompletedObesity | Muscle Weakness | Vitamin D Deficiency | Sarcopenia | Aging | Sarcopenic Obesity | Obesity (Disorder) | Sarcopenia in Elderly | Muscle Mass | Functional Decline | Age-Related Loss of Skeletal Muscle Mass | Older Adults (65 Years and Older) | Muscle Strengh | Vitamin D 25-Hydroxylase DeficiencyMexico
-
Umeå UniversityRegion SkaneCompleted
-
Bangladesh Medical UniversityEnrolling by invitationHypovitaminosis D | Major Depressive Disorder (MDD)Bangladesh
-
Karadeniz Technical UniversityActive, not recruitingThose Who Provided Written Informed Consent | Female Gender | Aged 18 Years and Older | Hypothyroidism Disease | Serum Vitamin d < 30 ng/dlTurkey (Türkiye)
-
Khon Kaen UniversityCompletedEndometriosis | Vitamin D Status | Vitamin D Deficiency/InsufficiencyThailand
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Bursa City HospitalCompletedVitamin D Deficiency | COVIDTurkey (Türkiye)